Match Document Document Title
US20120172297 SYNTHETIC HUMAN GENES AND POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES  
Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease,...
US20120204276 METHODS RELATED TO A MUTATION IN COMPLEMENT FACTOR H-RELATED PROTEIN 5 IN PATIENTS WITH GLOMERULONEPHRITIS  
The invention relates to methods of regulating complement. In particular, the inventors have identified a relationship between a particular gene, CFHR5, and irregularities in complement...
US20130287756 COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN  
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other...
US20110020316 COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN  
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other...
US20140073555 USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR TREATING CANCER OR INFLAMMATION  
A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising...
US20120021971 Functional Food Product Comprising Heat Shock Protein or a Hydrolysate Thereof  
The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic...
US20110152171 HISTAMINE BINDING PROTEIN  
The invention relates to histamine binding proteins. The invention also relates to the use of such histamine binding proteins in the treatment and prevention of diseases.
US20120082668 SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS  
Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and...
US20130136739 METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS  
Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a...
US20150239953 METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS  
Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
US20110177065 METHODS OF TREATING/PREVENTING INFLAMMATION USING COMBINATION OF IL-1 ANTAGONIST AND IL-18 BINDING PROTEIN  
The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases.
US20110256130 METHODS OF TREATING INFLAMMATORY DISORDERS  
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
US20140073572 TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES  
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and...
US20110015127 TARGETING COMPLEMENT FACTOR H FOR TREATMENT OF DISEASES  
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and...
US20150196618 METHODS FOR DIAGNOSING, PROGNOSING AND TREATING MUSCULAR DYSTROPHY  
Disclosed herein are methods for diagnosing, prognosing and treating muscular dystrophy. Also disclosed are methods of determining the effectiveness of an agent for the treatment of muscular...
US20100310508 METHODS OF TREATMENT INVOLVING p21/CIP1  
The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the...
US20120208743 USE OF GELSOLIN TO DIAGNOSE AND TREAT INFLAMMATORY DISEASES  
The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory...
US20140023634 COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA  
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline...
US20110195061 COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA  
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline...
US20100329985 TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES  
The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as...
US20110070237 METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM  
Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in...
US20120039867 Immune System Function in Conditions Characterized by Elevated Double Strand Breaks  
Methods and compositions for improving immune system function are provided. These methods find particular use in improving immune system function in individuals with a condition in which naïve...
US20110293727 CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAME  
Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a...
US20110124569 MACROCYCLIC COMPOUNDS, PROTEASE INHIBITION, AND METHODS OF TREATMENT  
The instant invention describes macrocyclic depsipeptide lyngbyastatins, and methods of treating disorders such as COPD, emphysema, rheumatoid arthritis, and aging related disorders.
US20110262396 COMBINATION TREATMENTS COMPRISING PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISORDERS  
Provided are methods and compositions for using protease binding proteins in combination with other therapeutic agents to treat inflammatory disorders such as rheumatoid arthritis, psoriasis,...
US20150246118 LYVE-1 ANTAGONISTS FOR PREVENTING OR TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH LYMPHANGIOGENESIS  
The present invention relates to the prevention or treatment of pathological conditions associated with lymphoangiogenesis (e.g. cancer and eye diseases). The present invention also relates to a...
US20110165144 METHODS FOR TREATING RHEUMATOID ARTHRITIS  
Provided are methods of treating rheumatoid arthritis by inhibiting Neuromedin U signalling.
US20100303923 Endotoxin adsorbent for the prevention and treatment of autoimmune diseases  
It is believed that the abnormal absorption of endotoxin present in the gastrointestinal tract relates to the pathogenesis of autoimmune diseases such as rheumatoid arthritis. In an animal model...
US20130315894 GENETIC POLYMORPHISMS ASSOCIATED WITH RHEUMATOID ARTHRITIS, METODS OF DETECTION AND USES THEREOF  
The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present...
US20110262386 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding...
US20110033469 LEUKOTRIENE B4 BINDING SOLUBLE LIPOCALIN RECEPTOR FROM IXODES RICINUS  
Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus, the polynucleotide and related polypeptides may be used as research reagents and materials for the development of treatments and...
US20130251713 METHODS FOR TREATING JUVENILE RHUMATOID ARTHRITIS BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE  
The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block...
US20140045756 METHODS AND COMPOSITIONS FOR MODULATING TNF/TNFR SIGNALING  
The present disclosure relates to methods and compositions for modulating TNF and TNFR signaling. In particular, the disclosure describes methods and compositions for inhibiting TNFα signaling,...
US20110059885 TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY EICOSANOIDS  
The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.
US20130150303 GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME  
Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and...
US20120046218 GLYCOSAMINOGLYCAN-ANTAGONISING MCP-I MUTANTS AND METHODS OF USING SAME  
Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and...
US20130330338 CTLA4 PROTEINS AND THEIR USES  
The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.
US20150037350 NEGATIVE MODULATOR OF HEDGEHOG SIGNALLING FOR USE IN TREATING TH2-MEDIATED DISEASES  
The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in...
US20140193333 THERAPEUTIC AND DIAGNOSTIC TARGET  
The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer,...
US20140037634 REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF  
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A...
US20130251821 VEGF-ACTIVATED FAS LIGANDS  
The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells...
US20110243923 ORGANIC COMPOUNDS  
The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or...
US20140135258 Treatment of Inflammatory Bowel Diseases with Mammal Beta Defensins  
The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
US20110166072 Polypeptides Selective for avB3 Integrin, Including Pegylated Polypeptides, And Pharmaceutical Uses Thereof  
The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective αvβ3 integrin antagonists for treatment and prevention of αvβ3 integrin-associated...
US20130164306 COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS  
Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
US20110104156 Methods and materials for treating autoimmune and/or complement mediated diseases and conditions  
Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the...
US20120141505 CD19-LIGAND AND USE  
Provided herein are CD19-ligand (CD19-L) polypeptides and polynucleotides encoding such CD19-L polypeptides. Methods related to diagnosing and treating a disorder associated with CD19 positive...
US20130108602 METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE  
Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject;...
US20130129668 Diagnosis and treatment of arthritis using epigenetics  
Embodiments of the present invention include methods, compositions and kits for evaluating a diagnosis, prognosis, or response to treatment of a subject with a disorder such as rheumatoid...
US20110195893 USE OF APOLIPOPROTEINS TO DECREASE INFLAMMATION  
The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory...